Last updated: November 12, 2026
SEZABY is Sun Pharmaceutical Industries’ U.S. injectable phenobarbital sodium product for seizures in term and near-term neonates. The FDA approved SEZABY on Oct. 17, 2022, creating the first FDA-approved phenobarbital product specifically labeled for neonatal seizures. Its commercial opportunity is narrow but defensible: demand is concentrated in neonatal intensive-care units, while adoption depends on replacing inexpensive generic phenobarbital and other off-label anticonvulsants with a standardized, FDA-approved product.
Sun does not publicly report SEZABY revenue as a separate line item. The product’s financial trajectory therefore must be assessed through its target population, hospital adoption, pricing, regulatory exclusivity, and the competitive position of generic phenobarbital.
What is SEZABY and which patients does it treat?
SEZABY contains phenobarbital sodium for intravenous use. It is indicated for the treatment of seizures in term and near-term neonates. The product is supplied as a 100 mg single-dose vial for reconstitution and intravenous administration. The FDA label specifies a loading dose of 20 mg/kg, with an additional 10 mg/kg if seizures continue or recur, followed by maintenance dosing.[1]
| Attribute |
SEZABY |
| Active ingredient |
Phenobarbital sodium |
| Dosage form |
Injectable powder for solution |
| Strength |
100 mg per vial |
| FDA approval |
Oct. 17, 2022 |
| Applicant/marketer |
Sun Pharmaceutical Industries, through its U.S. commercial operations |
| Indication |
Seizures in term and near-term neonates |
| Primary setting |
Neonatal intensive-care units |
| Administration |
Intravenous |
| Regulatory category |
New drug application |
| U.S. market status |
Commercially available |
Neonatal seizures are commonly associated with hypoxic-ischemic encephalopathy, stroke, intracranial hemorrhage, infection, metabolic disturbances, and genetic disorders. Treatment decisions are made in hospitals, which makes formulary placement and pharmacy protocols more important than direct-to-consumer promotion.
How large is the SEZABY market?
The addressable market is limited by the small number of annual neonatal seizure cases and by the availability of low-cost generic phenobarbital. The commercial opportunity is better defined as a hospital product market than as a broad neurology market.
The main demand drivers are:
- FDA labeling for neonatal seizures.
- Standardized vial strength and preparation instructions.
- Availability through commercial hospital distribution channels.
- Reduced reliance on extemporaneous pharmacy preparation.
- Institutional preference for products with defined manufacturing and quality controls.
- Clinical familiarity with phenobarbital as an initial treatment for neonatal seizures.
The main market constraints are:
- Low patient volume relative to adult neurology products.
- Generic phenobarbital availability.
- Use of levetiracetam and other anticonvulsants in some hospitals.
- Hospital budget controls and pharmacy-and-therapeutics review.
- Limited ability to expand into new indications without additional clinical evidence.
- Lack of a large outpatient or specialty-pharmacy channel.
Phenobarbital has long been used off label in neonates. SEZABY therefore competes against an entrenched standard of care rather than creating an entirely new treatment category. Its commercial value depends on whether hospitals pay for regulatory standardization and supply reliability.
What is the SEZABY financial trajectory?
Sun has not disclosed standalone SEZABY sales, product-level operating profit, or a separate revenue forecast in its principal public financial disclosures. The product is included within Sun’s broader specialty, innovative, or branded pharmaceutical operations rather than reported as an independent business segment.[2]
Revenue trajectory
SEZABY revenue likely follows a gradual hospital-adoption curve rather than a rapid launch pattern:
| Phase |
Financial characteristics |
| 2022 launch |
Initial stocking, formulary review, limited early utilization |
| 2023-2024 |
Expansion through neonatal intensive-care unit adoption and distributor coverage |
| 2025-2027 |
Potential maturation of hospital contracts and recurring use |
| 2028-2029 |
Revenue pressure if exclusivity ends without additional protection |
| Post-exclusivity |
Greater substitution risk from generic or alternative phenobarbital products |
The product can generate a high gross margin relative to manufacturing cost if the commercial price materially exceeds generic phenobarbital. That margin advantage may be offset by a small eligible population, hospital contracting discounts, inventory costs, and sales infrastructure.
Pricing and reimbursement
SEZABY’s economic proposition is likely based on a premium over generic phenobarbital. Exact net pricing is not publicly disclosed. Hospital purchasers typically evaluate the product against:
- Generic phenobarbital sodium injection.
- Pharmacy-compounded phenobarbital preparations.
- Levetiracetam injection.
- Fosphenytoin or phenytoin.
- Midazolam and other rescue therapies.
Reimbursement is generally embedded in inpatient hospital payment systems rather than paid through a separate retail prescription model. Hospitals therefore have an incentive to control acquisition cost unless SEZABY reduces preparation risk, medication errors, procurement complexity, or supply interruptions.
What patents protect SEZABY?
SEZABY’s strongest near-term protection is regulatory exclusivity, not an extensive disclosed patent estate. Phenobarbital is an old active ingredient, which limits the scope for broad composition-of-matter protection.
Potential protection categories include:
- The specific injectable presentation.
- Manufacturing and formulation processes.
- Dosage and administration methods.
- Stability, reconstitution, or packaging claims.
- FDA orphan-drug exclusivity.
- FDA approval-related exclusivity for clinical data.
Publicly available product information does not establish a broad, high-value patent thicket comparable with those surrounding complex biologics, long-acting injectables, or combination products. The commercial assessment should therefore focus on orphan-drug exclusivity, FDA labeling, manufacturing controls, and hospital adoption.
Does SEZABY have orphan-drug exclusivity?
The neonatal-seizure indication is associated with orphan-drug development because neonatal seizures affect a small patient population. If FDA orphan designation and approval exclusivity apply to the approved indication, the seven-year exclusivity period would generally run from the approval date and could extend into October 2029, subject to the exact FDA designation and exclusivity record.[3]
Orphan exclusivity prevents FDA approval of the same drug for the same orphan indication by another sponsor during the exclusivity period, subject to statutory exceptions. It does not prevent:
- Use of generic phenobarbital for other indications.
- Off-label use of other phenobarbital products.
- Approval of unrelated anticonvulsants.
- Competition based on different active ingredients.
- Hospital use of compounded products where legally permissible.
This distinction materially limits the economic effect of orphan protection.
When does SEZABY lose exclusivity?
The key commercial date is approximately October 2029 if the seven-year orphan exclusivity period began with the October 2022 approval. The precise date should be confirmed against FDA’s official orphan-drug designation and exclusivity records.
| Protection mechanism |
Estimated or known timing |
Commercial effect |
| FDA approval |
Oct. 17, 2022 |
Established labeled neonatal-seizure product |
| Orphan exclusivity |
Potentially through October 2029 |
Restricts same-drug approval for the same indication |
| New clinical investigation exclusivity |
Potentially three years, depending on FDA classification |
Limits certain FDA approvals relying on sponsor’s clinical data |
| Patent term |
Product-specific and not established here as a broad barrier |
Must be assessed from current Orange Book records |
| Generic entry |
Most relevant after regulatory barriers expire or through non-identical products |
Could pressure price and share |
Generic phenobarbital can remain a competitive threat during SEZABY’s exclusivity period because orphan exclusivity is indication-specific. The practical question is not whether generic phenobarbital can exist, but whether a competing sponsor can obtain approval for the same neonatal-seizure indication using the same active ingredient and dosage form.
What is the Orange Book status of SEZABY?
SEZABY is an FDA-approved prescription drug under an NDA. The FDA Orange Book is the controlling source for any listed patents, expiration dates, and submission certifications.[4]
The principal regulatory risk is that SEZABY may have limited Orange Book patent coverage because phenobarbital is an established compound and the product’s differentiation is concentrated in its indication, presentation, and manufacturing platform. A listed patent covering a specific formulation or method of use could delay an approved generic product, but it would not eliminate competition from generic phenobarbital used under a different label.
The Orange Book assessment should distinguish among:
- Patents listed against the SEZABY NDA.
- Patents covering the active ingredient, if any.
- Method-of-use patents covering neonatal seizures.
- Formulation or packaging patents.
- Patent certifications submitted by generic applicants.
- Regulatory exclusivity separate from patent protection.
Are there Paragraph IV challenges to SEZABY?
No material publicly reported Paragraph IV litigation involving SEZABY was identified in the public record available for this analysis. That does not establish that no certification, notice letter, or confidential commercial challenge exists.
A Paragraph IV challenge would be relevant if a generic applicant files an ANDA asserting that an Orange Book-listed SEZABY patent is invalid, unenforceable, or not infringed. The litigation risk would depend on:
- The number and scope of listed patents.
- Whether claims cover the product or only the neonatal-seizure use.
- The timing of the generic filing.
- The availability of alternative generic phenobarbital products.
- The effect of orphan-drug exclusivity on FDA approval timing.
Because the active ingredient is old, a generic challenger may have a stronger pathway than in a newly discovered drug. The principal barriers are likely indication-specific regulatory exclusivity and product-specific manufacturing requirements rather than molecule-level patent claims.
What formulations are protected by SEZABY?
SEZABY’s commercial differentiation is tied to its injectable presentation for neonatal use. The formulation and manufacturing package may provide practical protection even if it does not create a broad patent barrier.
Relevant technical attributes include:
- A defined 100 mg vial presentation.
- Intravenous reconstitution.
- Hospital-focused dosing.
- Manufacturing under FDA quality requirements.
- Labeling for term and near-term neonates.
- Controlled preparation and administration instructions.
A competing manufacturer could potentially develop a phenobarbital injection with a different concentration, vial size, excipient profile, or manufacturing process. Such a product could compete clinically while avoiding claims limited to SEZABY’s exact formulation.
Formulation patents are most valuable when they cover a technically difficult stability, solubility, delivery, or packaging problem. Phenobarbital injection is a mature dosage form, which reduces the likelihood that formulation protection alone will sustain a long commercial life.
How does SEZABY compare with generic phenobarbital and levetiracetam?
| Factor |
SEZABY |
Generic phenobarbital |
Levetiracetam |
| FDA-labeled neonatal-seizure indication |
Yes |
Product-specific labeling may differ |
Not necessarily for neonatal seizures |
| Active ingredient |
Phenobarbital sodium |
Phenobarbital sodium |
Levetiracetam |
| Clinical familiarity |
High |
High |
Increasing |
| Cost |
Premium branded product |
Low-cost generic |
Variable |
| Hospital preparation |
Standardized commercial vial |
Product and institution dependent |
Commercial injection available |
| Patent risk |
Product-specific |
Generally low |
Product-specific and largely mature |
| Main advantage |
FDA-labeled standardized neonatal use |
Price |
Alternative safety and tolerability profile |
| Main commercial threat |
Generic substitution and off-label alternatives |
Low price |
Clinical switching and protocol preference |
Phenobarbital remains an important treatment option, but hospital protocols can change as evidence and clinician preferences evolve. Levetiracetam may gain use where clinicians seek a different adverse-event profile or avoid phenobarbital-related sedation and respiratory effects.
Which companies are challenging SEZABY?
No major publicly reported company has emerged as a confirmed litigation challenger to SEZABY. The likely competitive set includes:
- Generic injectable manufacturers.
- Hospital-compounding pharmacies.
- Manufacturers of levetiracetam injection.
- Suppliers of fosphenytoin, phenytoin, and midazolam.
- Future sponsors seeking approval for neonatal seizure therapies.
The most credible competitive threat is not necessarily a direct SEZABY generic. Hospitals can continue purchasing generic phenobarbital or choose another anticonvulsant. That creates a lower threshold for competitive pressure than a conventional branded drug facing only an ANDA competitor.
What litigation and settlement agreements affect SEZABY?
No material publicly reported patent litigation or settlement agreement affecting SEZABY was identified in the available record. The absence of litigation is consistent with a product whose protection may depend more heavily on regulatory exclusivity and commercial execution than on a dense patent portfolio.
Future litigation could arise from:
- A generic ANDA with a Paragraph IV certification.
- A dispute over a formulation or method-of-use patent.
- A challenge to orphan exclusivity.
- A manufacturing or supply agreement dispute.
- False-marking, labeling, or regulatory claims.
A settlement could delay a competing product until the end of orphan exclusivity or an asserted patent term. Its value would be limited if hospitals can already use generic phenobarbital off label.
What is SEZABY’s FDA regulatory status?
SEZABY is FDA approved and marketed in the United States. Its approval addressed a significant regulatory gap: clinicians had used phenobarbital in neonates for many years, but the product was not previously available as an FDA-approved neonatal-seizure therapy in this specific commercial form.[1]
The FDA label remains central to commercialization because it supports:
- Hospital formulary review.
- Institutional treatment protocols.
- Pharmacist procurement.
- Medical education.
- Consistent dosing and preparation.
- Regulatory-compliant promotion.
The label does not give Sun exclusive control over phenobarbital treatment of neonatal seizures. It gives SEZABY a regulated product and a protected indication during the applicable exclusivity period.
What generic launch scenarios exist for SEZABY?
Scenario 1: Direct same-indication generic entry after exclusivity
A generic sponsor launches an injectable phenobarbital product labeled for neonatal seizures after regulatory exclusivity expires. This would create the highest direct pricing pressure.
Scenario 2: Off-label generic substitution before direct entry
Hospitals continue using generic phenobarbital for neonatal seizures. This scenario already limits SEZABY’s market share and may be more important than a future ANDA launch.
Scenario 3: Alternative anticonvulsant displacement
Levetiracetam or another agent gains use in neonatal protocols. This would reduce the addressable SEZABY market without requiring a patent challenge.
Scenario 4: Limited premium niche
SEZABY retains use in hospitals that value FDA labeling, standardized preparation, and supply reliability. Revenue remains modest but durable through the exclusivity period.
The most probable commercial outcome is a constrained specialty product with stable institutional demand, rather than a blockbuster trajectory.
What licensing deals support SEZABY?
No major publicly disclosed third-party licensing transaction was identified as the principal basis for SEZABY’s commercialization. Sun Pharmaceutical Industries is the relevant commercial sponsor and marketer in the United States.
The absence of a prominent licensing deal reduces visibility into:
- Upfront payments.
- Milestone obligations.
- Royalty rates.
- Territory rights.
- Co-commercialization arrangements.
- Transfer of manufacturing rights.
SEZABY’s economics therefore appear primarily tied to Sun’s internal commercialization and manufacturing structure.
What is the geographic coverage of SEZABY?
The commercially established market is the United States. FDA approval does not automatically create approval or marketing rights in Europe, Japan, Canada, or other jurisdictions.
International expansion would require:
- Local regulatory approval.
- Country-specific neonatal seizure data and labeling.
- Pricing and reimbursement negotiations.
- Local distribution.
- Manufacturing and pharmacovigilance infrastructure.
A U.S.-only product has a narrower revenue ceiling but also avoids the cost of building a global specialty launch. No broad international commercial footprint is established in the cited public materials.
How strong is the SEZABY patent estate?
SEZABY has a moderate commercial protection profile and a weaker classical patent profile.
| Protection factor |
Assessment |
| Active-ingredient patent |
Weak or unavailable because phenobarbital is old |
| FDA approval |
Strong for labeled use and institutional credibility |
| Orphan exclusivity |
Potentially meaningful through approximately October 2029 |
| Formulation protection |
Potentially useful but likely narrow |
| Method-of-use protection |
Potentially relevant to neonatal seizures |
| Manufacturing barriers |
Moderate practical barrier |
| Generic substitution risk |
High because generic phenobarbital is available |
| Litigation deterrence |
Limited without a broad listed patent estate |
| Long-term pricing power |
Low to moderate |
The product’s strongest moat is the combination of regulatory approval, neonatal-unit access, physician familiarity, and hospital workflow integration. Those advantages can support sales but are less durable than composition-of-matter patents.
Key Takeaways
- SEZABY is an FDA-approved intravenous phenobarbital sodium product for seizures in term and near-term neonates.
- Its market is concentrated in neonatal intensive-care units and is structurally small.
- Sun has not disclosed standalone SEZABY revenue, so financial performance cannot be measured directly from public reporting.
- Generic phenobarbital is the principal commercial constraint because it can be used off label.
- Orphan-drug exclusivity could protect the same approved indication through approximately October 2029, subject to confirmation in FDA records.
- No material publicly reported Paragraph IV litigation or settlement agreement was identified.
- SEZABY’s patent strength appears narrower than its regulatory and commercial positioning.
- The likely financial trajectory is gradual hospital adoption followed by limited but durable specialty revenue, with increasing pricing pressure as exclusivity expires.
- Direct generic entry is only one risk. Off-label generic substitution and levetiracetam use can constrain sales before a direct SEZABY generic launches.
FAQs
Is SEZABY a blockbuster drug?
No. Its target population is limited to neonates with seizures, and generic phenobarbital is available. SEZABY is more likely to produce specialty-product revenue than blockbuster-scale sales.
Can generic phenobarbital compete with SEZABY before 2029?
Yes. Generic phenobarbital can be used for neonatal seizures outside SEZABY’s protected FDA indication. Orphan exclusivity generally does not prohibit off-label use of an existing generic product.
Does SEZABY have composition-of-matter patent protection?
Broad composition-of-matter protection is unlikely because phenobarbital is an established active ingredient. Any meaningful patent protection would more likely involve formulation, manufacturing, packaging, or method-of-use claims.
What is the biggest commercial risk to SEZABY?
The biggest risk is hospital substitution with low-cost generic phenobarbital or alternative anticonvulsants. A direct ANDA challenge is not required to constrain SEZABY revenue.
Is SEZABY approved outside the United States?
The cited FDA materials establish U.S. approval. They do not establish a broad international approval or commercialization program.
References
- U.S. Food and Drug Administration. (2022). SEZABY (phenobarbital sodium) for injection prescribing information.
- Sun Pharmaceutical Industries Limited. (2024). Annual report 2023-2024.
- U.S. Food and Drug Administration. (n.d.). Orphan drug designations and approvals database.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.